ArticleInternational journal of molecular sciences2026
Cyclodextrin-Mediated Enantiomeric Separation of Idelalisib: A Validated Capillary Electrophoresis and NMR Study.
Erzsébet Várnagy, Balázs István Urbán, Mátyás Sári, Balázs Volk, Gyula Simig, Krisztina Németh, Milo Malanga, Ida Fejős, Szabolcs Béni
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Erzsébet VárnagyDepartment of Pharmacognosy, Semmelweis University, Üllői út 26, H-1085 Budapest, Hungary.
Balázs István UrbánIntegrative Health and Environmental Analysis Research Laboratory, Department of Analytical Chemistry, Institute of Chemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/A, H-1117 Budapest, Hungary.
Mátyás SáriIntegrative Health and Environmental Analysis Research Laboratory, Department of Analytical Chemistry, Institute of Chemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/A, H-1117 Budapest, Hungary.
Balázs VolkDirectorate of Drug Substance Development, Egis Pharmaceuticals Plc., P.O. Box 100, H-1475 Budapest, Hungary.ORCID 0000-0002-2019-1874 Gyula SimigDirectorate of Drug Substance Development, Egis Pharmaceuticals Plc., P.O. Box 100, H-1475 Budapest, Hungary.ORCID 0000-0002-2569-6476 Krisztina NémethChemical Biology Research Group, Institute of Organic Chemistry, HUN-REN Research Centre for Natural Sciences, Magyar Tudósok Krt. 2, H-1117 Budapest, Hungary.ORCID 0000-0003-1360-7648 Milo MalangaCarboHyde Ltd., Berlini u. 47-49, H-1045 Budapest, Hungary.
Szabolcs BéniIntegrative Health and Environmental Analysis Research Laboratory, Department of Analytical Chemistry, Institute of Chemistry, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/A, H-1117 Budapest, Hungary.ORCID 0000-0001-7056-6825 Funding
European Union's Horizon Europe research and innovation program under the Marie Sklodowska-Curie grant agreement Bicyclos N◦ 101130235
6 · The paper itselfAbstract
Idelalisib (IDE) is a marketed chiral anticancer drug administered as the
Indexed as
CyclodextrinsPurines2-Hydroxypropyl-beta-cyclodextrinElectrophoresis, CapillaryMagnetic Resonance SpectroscopyStereoisomerism2-Hydroxypropyl-beta-cyclodextrinCyclodextrinsPurines19F NMR1H-19F HOESY NMR2D ROESY NMRchiral impurity profilingdesign of experimentsdiastereomeric splittinghost-guest complexationhydroxypropyl-β-cyclodextrin chiral selectorselective phosphoinositide 3-kinase delta inhibitorvariable temperature NMR
Identifiers
PMID42450301
PMCPMC13360804
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390